1. Report Industry Investment Rating - Not provided in the report 2. Core Viewpoints of the Report - The target price of Boshi Convertible Bond on the first day of listing is estimated to be between 104 - 108 yuan, and investors are advised to actively subscribe [3][17] - The estimated first - day new - bond subscription winning rate is around 0.0023% - 0.0025% [4][18] 3. Summary According to the Directory 3.1 Doctor Convertible Bond New - Bond Analysis and Investment Recommendations 3.1.1 Convertible Bond Basic Terms Analysis - The issuance method of Boshi Convertible Bond is priority placement and online issuance, with both the bond and the issuer rated AA. The issuance scale is 375 million yuan, the initial conversion price is 30.43 yuan. As of March 20, 2026, the convertible bond parity is 81.07 yuan, the calculated pure bond value is 100.79 yuan. The game terms are normal. Overall, the bond issuance scale is low, liquidity is poor, the rating is acceptable, and the bond floor protection is good [2][13] 3.1.2 New - Bond Initial Listing Price Analysis - The company's main business is to provide consumers with fashionable and personalized eyewear products and professional visual health solutions. The raised funds will be used for chain eyewear store construction and upgrading, headquarters operation management center and brand building, digital platform upgrading, and supplementing working capital. The convertible bond's first - day conversion premium rate is expected to be in the range of [28%, 33%], corresponding to a first - day listing target price around 104 - 108 yuan [3][16][17] 3.1.3 Convertible Bond New - Bond Subscription Winning Rate Analysis - Assuming the old shareholders' placement ratio is 40% - 45%, the scale of Boshi Convertible Bond available to the market is 207 million - 223 million yuan. Assuming the online effective subscription number is 8.88 million households, the winning rate is around 0.0023% - 0.0025% [4][18] 3.2 Underlying Stock Fundamental Analysis 3.2.1 Company's Main Business and Industry Up - and Downstream Situations - The company focuses on providing fashionable and personalized eyewear products and professional visual health solutions. The upstream of the industry consists of raw material and equipment suppliers, and the downstream is diversified sales channels, with offline stores being the main sales place [19][20][21] 3.2.2 Company's Operating Conditions - The company's revenue has been rising in recent years. From 2022 to the first three quarters of 2025, the revenue was 962 million yuan, 1.176 billion yuan, 1.203 billion yuan, and 1.08 billion yuan respectively, with year - on - year growth rates of 8.42%, 22.20%, 2.29%, and 18.05%. The comprehensive gross profit margin has remained stable, and the net profit margin has also been relatively stable. The company's R & D expenses have been increasing, and the accounts receivable turnover rate has been generally stable, but the accounts receivable as a proportion of revenue has been rising. The net profit attributable to the parent company has fluctuated greatly [23][27][32] 3.2.3 Company's Equity Structure and Main Subsidiaries - As of September 30, 2025, the company's equity structure is relatively concentrated. The top two shareholders hold 40.44% of the shares, and the top ten shareholders hold 44.92% of the shares. The actual controllers and their concerted parties hold 40.75% of the shares, and the controlling shareholder and actual controller have not changed since listing [39] 3.2.4 Company's Business Characteristics and Advantages - The company has brand, sales channel, product, and service and delivery advantages. It has a high - profile brand, a wide - spread sales network, a diverse product portfolio, and efficient service and delivery capabilities [44][45][46] 3.2.5 Allocation of Raised Funds - The company plans to issue convertible bonds to raise 375 million yuan. After deducting issuance fees, 180 million yuan will be used for chain eyewear store construction and upgrading, 70 million yuan for the headquarters operation management center and brand building, 70 million yuan for digital platform upgrading, and 55 million yuan for supplementing working capital [11][16][47]

Group 1 - The core viewpoint of the news is that 博士眼镜 (Doctor Glasses) has shown significant stock performance and financial growth, with a notable increase in share price and revenue [1][2]. - As of January 20, the stock price of 博士眼镜 increased by 2.04% to 34.52 CNY per share, with a total market capitalization of 7.866 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 11.14%, with a 6.51% rise over the last five trading days and a 19.16% increase over the last 20 days [1]. Group 2 - For the period from January to September 2025, 博士眼镜 reported a revenue of 1.08 billion CNY, representing a year-on-year growth of 18.05%, and a net profit attributable to shareholders of 87.8313 million CNY, up 5.21% [2]. - The company has distributed a total of 464 million CNY in dividends since its A-share listing, with 204 million CNY distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders for 博士眼镜 decreased by 19.71% to 43,200, while the average number of circulating shares per person increased by 24.54% to 3,602 shares [2][3].

Group 1 - The core viewpoint of the news is that 博士眼镜 (Doctor Glasses) has shown positive stock performance and financial growth, with a notable increase in revenue and net profit year-on-year [1][2]. - As of January 12, the stock price of 博士眼镜 increased by 2.01% to 33.06 yuan per share, with a total market capitalization of 75.33 billion yuan [1]. - The company has experienced a stock price increase of 6.44% year-to-date, with significant gains over various trading periods: 2.86% over the last 5 days, 7.86% over the last 20 days, and 11.28% over the last 60 days [1]. Group 2 - For the period from January to September 2025, 博士眼镜 achieved operating revenue of 1.08 billion yuan, representing a year-on-year growth of 18.05%, and a net profit attributable to shareholders of 87.83 million yuan, up 5.21% year-on-year [2]. - The company has distributed a total of 464 million yuan in dividends since its A-share listing, with 204 million yuan distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders for 博士眼镜 decreased by 19.71% to 43,200, while the average number of circulating shares per person increased by 24.54% to 3,602 shares [2][3].

Core Viewpoint - Dr. Optical's stock has shown volatility with a year-to-date decline of 18.92%, but a recent uptick of 6.53% over the last five trading days indicates potential recovery [1] Group 1: Stock Performance - As of December 29, Dr. Optical's stock price is 30.99 CNY per share, with a market capitalization of 7.061 billion CNY [1] - The stock has experienced a trading volume of 1.50 billion CNY and a turnover rate of 3.16% [1] - The stock has been on the "龙虎榜" (Dragon and Tiger List) twice this year, with the latest instance on February 21, showing a net buy of -235 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Dr. Optical reported a revenue of 1.08 billion CNY, reflecting a year-on-year growth of 18.05% [2] - The net profit attributable to the parent company for the same period was 87.83 million CNY, marking a growth of 5.21% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dr. Optical is 43,200, a decrease of 19.71% from the previous period [2] - The average number of circulating shares per shareholder has increased by 24.54% to 3,602 shares [2] - The company has distributed a total of 464 million CNY in dividends since its A-share listing, with 204 million CNY distributed in the last three years [3]

Group 1 - The stock price of Dr. Optical fell by 5.06% to 28.31 yuan per share, with a trading volume of 145 million yuan and a turnover rate of 3.22%, resulting in a total market capitalization of 6.451 billion yuan [1] - Dr. Optical, established on April 23, 1997, and listed on March 15, 2017, is primarily engaged in optical retail, with revenue composition as follows: optical glasses and fitting services 68.65%, finished glasses series products 19.47%, contact lenses series products 10.80%, and others 1.09% [1] Group 2 - Minsheng Jia Yin Fund's Minsheng Jia Yin Sustained Growth Mixed A (007731) is among the top ten circulating shareholders of Dr. Optical, having increased its holdings by 418,700 shares to a total of 1.9187 million shares, representing 1.23% of circulating shares [2] - The fund has incurred an estimated floating loss of approximately 2.8972 million yuan as of the report date [2] - Minsheng Jia Yin Sustained Growth Mixed A was established on September 24, 2019, with a current scale of 1.394 billion yuan, achieving a year-to-date return of 25.57% and a one-year return of 23.58% [2] Group 3 - The fund manager of Minsheng Jia Yin Sustained Growth Mixed A is Zhu Chenzhe, who has been in position for 3 years and 343 days, with a total asset scale of 1.792 billion yuan and a best fund return of 10.8% during his tenure [3] - Co-manager Fan Mingyue has been in position for 306 days, managing assets totaling 1.857 billion yuan, with a best fund return of 26.53% during his tenure [3]

Core Viewpoint - Dr. Optical's stock price increased by 5.11% to 31.66 CNY per share, with a trading volume of 279 million CNY and a turnover rate of 5.93%, resulting in a total market capitalization of 7.214 billion CNY [1] Group 1: Company Overview - Dr. Optical Chain Co., Ltd. is located in Shenzhen, Guangdong Province, and was established on April 23, 1997, with its listing date on March 15, 2017 [1] - The company's main business involves optical retail, with revenue composition as follows: optical glasses and fitting services 68.65%, finished glasses series products 19.47%, contact lens series products 10.80%, and others 1.09% [1] Group 2: Shareholder Information - Minsheng Jia Yin Fund's Minsheng Jia Yin Sustained Growth Mixed A (007731) is among the top ten circulating shareholders of Dr. Optical, having increased its holdings by 418,700 shares to a total of 1.9187 million shares, representing 1.23% of circulating shares [2] - The fund has achieved a year-to-date return of 28.25%, ranking 2995 out of 8140 in its category, and a one-year return of 25.27%, ranking 3257 out of 8057 [2] Group 3: Fund Manager Performance - The fund manager Zhu Chenzhe has been in position for 3 years and 340 days, managing assets totaling 1.792 billion CNY, with the best fund return during his tenure at 10.69% and the worst at -7.37% [3] - Co-manager Fan Mingyue has been in position for 303 days, managing assets of 1.857 billion CNY, with the best fund return at 26.02% and the worst at -3.15% [3]

Core Viewpoint - Dr. Optical's stock price has experienced a decline of 21.28% year-to-date, with recent fluctuations indicating a potential recovery in the short term [2] Group 1: Stock Performance - As of October 21, Dr. Optical's stock rose by 2.00%, reaching a price of 30.09 CNY per share, with a total market capitalization of 6.856 billion CNY [1] - The stock has seen a net inflow of 3.8985 million CNY from major funds, with large orders accounting for 19.30% of total purchases [1] - Over the past five trading days, the stock has increased by 1.90%, while it has decreased by 13.66% over the past 20 days and 12.38% over the past 60 days [2] Group 2: Financial Performance - For the first half of 2025, Dr. Optical reported a revenue of 686 million CNY, reflecting a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 56.0334 million CNY, up by 6.97% [3] - Since its A-share listing, the company has distributed a total of 464 million CNY in dividends, with 204 million CNY distributed over the past three years [4] Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 53,800, with an average of 2,892 circulating shares per person, marking an increase of 19.81% [3] - Notable new institutional shareholders include Guangfa Innovation Upgrade Mixed Fund and Minsheng Jia Yin Continuous Growth Mixed Fund, both entering the top ten circulating shareholders [4]

Core Viewpoint - Dr. Optical's stock has experienced a significant decline this year, with a year-to-date drop of 22.22%, indicating potential challenges in the retail optical market [1][2]. Financial Performance - For the first half of 2025, Dr. Optical achieved a revenue of 686 million yuan, representing a year-on-year growth of 14.22%, while the net profit attributable to shareholders was 56.03 million yuan, up 6.97% year-on-year [2]. - The company has distributed a total of 464 million yuan in dividends since its A-share listing, with 204 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 14, Dr. Optical's stock price was 29.73 yuan per share, with a market capitalization of 6.774 billion yuan. The stock has seen a trading volume of 150 million yuan and a turnover rate of 3.20% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent instance on February 21, where it recorded a net buy of -235 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Dr. Optical increased to 53,800, a rise of 9.25% from the previous period, with an average of 2,892 circulating shares per shareholder, up 19.81% [2]. - Notable new institutional shareholders include Guangfa Innovation Upgrade Mixed Fund and Minsheng Jia Yin Continuous Growth Mixed Fund, which are now among the top ten circulating shareholders [3]. Business Overview - Dr. Optical, established on April 23, 1997, and listed on March 15, 2017, primarily engages in optical retail, with its revenue composition being 68.65% from optical glasses and fitting services, 19.47% from finished lens products, and 10.80% from contact lens products [1].

Company Overview - 博士眼镜 is a retail company specializing in eyewear, established on April 23, 1997, and listed on March 15, 2017 [1] - The company is located in Shenzhen, Guangdong Province, and its main business includes optical glasses and fitting services, accounting for 67.01% of its revenue [1] Financial Performance - For the first half of 2025, 博士眼镜 achieved a revenue of 686 million yuan, representing a year-on-year growth of 14.22% [2] - The net profit attributable to the parent company for the same period was 56.03 million yuan, an increase of 6.97% year-on-year [2] - Cumulatively, the company has distributed 464 million yuan in dividends since its A-share listing, with 204 million yuan in the last three years [3] Stock Market Activity - As of September 10, 博士眼镜's stock price was 34.26 yuan per share, with a market capitalization of 7.806 billion yuan [1] - The stock has seen a decline of 10.37% year-to-date, with a slight increase of 1.66% over the last five trading days [1] - The company has appeared on the龙虎榜 twice this year, with the most recent net buy of -235 million yuan on February 21 [1] Shareholder Information - As of June 30, 2025, 博士眼镜 had 53,800 shareholders, an increase of 9.25% from the previous period [2] - The average number of circulating shares per shareholder was 2,892, up by 19.81% [2] - New institutional shareholders include 广发创新升级混合 and 民生加银持续成长混合A, while some previous shareholders have exited the top ten list [3] Market Position - 博士眼镜 operates within the 商贸零售-专业连锁 industry and is associated with concepts such as small-cap stocks, smart glasses, and wearable technology [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price not specified [7][6] Core Views - The company reported a revenue of 288 million in Q4 2024, a year-on-year increase of 6.3%, while the net profit attributable to the parent company was 20 million, down 33.9% year-on-year [1] - For the full year 2024, the company achieved a revenue of 1.203 billion, a 2.3% increase year-on-year, but the net profit attributable to the parent company decreased by 19.1% to 104 million [1] - The company is actively implementing a marketing strategy focused on core regions and a combination of online and offline channels, which has led to steady revenue growth despite a decline in profits due to goodwill impairment [1] Financial Performance - The company's gross margin for 2024 was 61.71%, a decrease of 1.36 percentage points, and the net profit margin was 8.62%, down 2.28 percentage points [1] - The revenue from optical glasses and fitting services was 806 million, up 1.78% year-on-year, with a gross margin of 70.2% [2] - The revenue from the complete glasses series was 178 million, an increase of 11.97%, with a gross margin of 46.8% [2] - The revenue from contact lenses decreased by 5.03% to 156 million, with a gross margin of 36.9% [2] Product Structure Optimization - The company has cultivated its own brands, owning 13 brands by the end of 2024, with self-branded lenses and frames accounting for 58.65% and 65.40% of total sales, respectively [3] - Sales of functional lenses and adult progressive lenses saw significant year-on-year growth, with increases of 33.87% and 7.28%, respectively [3] Store Expansion and Digital Transformation - By the end of 2024, the company had 557 stores, a net increase of 42, with 510 direct-operated stores [4] - The company is deepening partnerships with major supermarket chains and hospitals to enhance its retail presence in key urban areas [4] - Online sales totaled 190 million in 2024, a decrease of 7.83% year-on-year, but the company is focusing on increasing brand exposure through social media and live streaming [4] Embracing Smart Technology - The company is actively engaging in the smart eyewear market, collaborating with leading brands to enhance its service offerings [5] - The launch of the Thunder V3 AI shooting glasses is scheduled for January 7, 2025, with plans to upgrade retail stores to include smart eyewear displays [5] Profit Forecast Adjustments - The profit forecast has been adjusted, with expected net profits for 2025, 2026, and 2027 at 120 million, 140 million, and 160 million, respectively [11]